|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2011-5-23
|
|
pubmed:abstractText |
Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer that can originate from activating mutations or rearrangements in the RET gene. Therapeutic options are limited in recurrent disease, but because RET is a tyrosine kinase (TK) receptor involved in cellular growth and proliferation, treatment with a TK inhibitor might be promising. Several TK inhibitors have been tested in clinical trials, but it is unknown which inhibitor is most effective and whether there is any specificity for particular RET mutations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anilides,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Indazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/N-(4-bromo-2-fluorophenyl)-6-methoxy...,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-ret,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/RET protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor Protein-Tyrosine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/axitinib,
http://linkedlifedata.com/resource/pubmed/chemical/cabozantinib,
http://linkedlifedata.com/resource/pubmed/chemical/sunitinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1945-7197
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
E991-5
|
|
pubmed:meshHeading |
pubmed-meshheading:21470995-Anilides,
pubmed-meshheading:21470995-Blotting, Western,
pubmed-meshheading:21470995-Cell Line, Tumor,
pubmed-meshheading:21470995-Cell Proliferation,
pubmed-meshheading:21470995-Humans,
pubmed-meshheading:21470995-Imidazoles,
pubmed-meshheading:21470995-Indazoles,
pubmed-meshheading:21470995-Indoles,
pubmed-meshheading:21470995-Phosphorylation,
pubmed-meshheading:21470995-Piperidines,
pubmed-meshheading:21470995-Protein Kinase Inhibitors,
pubmed-meshheading:21470995-Proto-Oncogene Proteins c-ret,
pubmed-meshheading:21470995-Pyridines,
pubmed-meshheading:21470995-Pyrroles,
pubmed-meshheading:21470995-Quinazolines,
pubmed-meshheading:21470995-Receptor Protein-Tyrosine Kinases,
pubmed-meshheading:21470995-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:21470995-Signal Transduction,
pubmed-meshheading:21470995-Thyroid Gland,
pubmed-meshheading:21470995-Tumor Cells, Cultured
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
|
|
pubmed:affiliation |
Department of Genetics, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
